Q4 2024 Earnings Call Transcript March 5, 2025 EyePoint Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.54. Tessa Romero – JPMorgan: Yigal ...

Detailed price information for Adverum Biotechnologies Inc (ADVM-Q) from The Globe and Mail including charting and trades.

CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD - - Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other ...

Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...

Q4 2024 Earnings Call Transcript March 3, 2025 Ocular Therapeutix, Inc. misses on earnings expectations. Reported EPS is ...

Adverum Biotechnologies (ADVM) announced the initiation of the ARTEMIS Phase 3 study. This pivotal trial is designed to evaluate the efficacy ...

Older patients with diabetic macular edema have a weaker response to anti-VEGF treatment, according to a presentation at ...

Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 ...

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMDARTEMIS ...

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populatio ...